Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Announces Year End 2017 Financial Results
LEXINGTON, Mass. , March 29, 2018 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced financial results for the year ended
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results
LEXINGTON, Mass. , March 22, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, will issue financial results for the year ended December
View HTML
Toggle Summary Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases
LEXINGTON, Mass. , Feb. 27, 2018 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has entered into a collaborative
View HTML
Toggle Summary Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Poster Presentations to Feature Phase 2b Allergic Conjunctivitis Results, in Addition to Activity of Reproxalap and ADX-103 in Models of Retinal Inflammation, Diabetic Macular Edema, and Dry Age-Related Macular Degeneration
View HTML
Toggle Summary Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial
LEXINGTON, Mass. , Jan. 30, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation and inborn errors of metabolism, today announced that it has enrolled the first patient in a Phase 2b clinical trial of
View HTML
Toggle Summary Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
New Analyses Demonstrate Statistical Non-Inferiority of 0.5% Reproxalap Ophthalmic Solution to Corticosteroid
View HTML
Toggle Summary Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results
LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced
View HTML
Toggle Summary Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference
LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results
LEXINGTON, Mass. , Nov. 2, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will issue
View HTML
Toggle Summary Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting
LEXINGTON, Mass. , Oct. 25, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will present
View HTML